Abstract Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide. Effective treatments against …

In acute coronavirus disease 19 (COVID‐19) patients, effective clinical risk stratification has
important implications on treatment and therapeutic resource distribution. This article …

Introduction The SARS-CoV-2 outbreak has threatened the human population globally as
the numbers of reinfection cases even after large-scale vaccination. Trials have been carried …

The efficacy on the Omicron variant of the approved early coronavirus disease‐2019
(COVID‐19) therapies, especially monoclonal antibodies, has been challenged by in vitro …

The aim of this meta-analysis is to evaluate the efficacy of molnupiravir among mild or
moderate COVID-19 patients. This meta-analysis was reported according to the guidelines …

Background: Limited treatment options exist for patients with mild-to-moderate coronavirus
disease 2019 (COVID-19), irrespective of vaccination history or risk status. Ensitrelvir is a …

Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the
treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main …

Background. Molnupiravir (MOL) and nirmatrelvir/ritonavir (NIR) were recently approved for
the early treatment of COVID-19, but real-life data on tolerability, safety, and adverse events …

The SARS-CoV-2 pandemic is considered as one of the most disastrous pandemics for
human health and the world economy. RNA-dependent RNA polymerase (RdRp) is one of …

Several randomized controlled trials and real‐world cohort studies have demonstrated the
efficacies of nirmatrelvir plus ritonavir (NMV‐r) and molnupiravir (MOV) in at‐risk patients …